Profil bibliographique

Thomas Chalopin

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

83Publications signalées

740Citations signalées

3Affiliations récentes

Institutions déclarées

Université de Tours Centre Hospitalier Universitaire de Tours Hôpital Bretonneau

Domaines associés

Multiple Myeloma Research and TreatmentsProtein Degradation and InhibitorsPeptidase Inhibition and AnalysisCancer Treatment and PharmacologyMonoclonal and Polyclonal Antibodies Research

Publications récentes

2026 conference-abstractOpenAlex

MM-937: Comparative Analysis of Subcutaneous Isa VRd (ISASOCUT) and Intravenous Isa VRd (IMROZ) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Across Age Groups

Arthur Bobin, Mohamad Mohty, Philippe Moreau, Hartmut Goldschmidt et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

POSTER: MM-937: Comparative Analysis of Subcutaneous Isa VRd (ISASOCUT) and Intravenous Isa VRd (IMROZ) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Across Age Groups

Arthur Bobin, Mohamad Mohty, Philippe Moreau, Hartmut Goldschmidt et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Accès ouvert 2026 articleOpenAlex

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial

Aurore Perrot, Cyrille Touzeau, Stéphane Minvielle, Cyrille Hulin et autres

0 citationsBlood Cancer Journal

Accès ouvert 2026 articleOpenAlex

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials

Ashutosh D. Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis et autres

1 citationJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Comparative analysis of subcutaneous Isa VRd (ISASOCUT) and intravenous Isa VRd (IMROZ) in transplant-ineligible newly diagnosed multiple myeloma across age groups.

Arthur Bobin, Mohamad Mohty, Philippe Moreau, H Goldschmidt et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Safety and efficacy of elranatamab as early intervention in patients with high-risk smoldering myeloma: First results from the phase 2 ERASMM (EMN34) study.

Cyrille Touzeau, Fredrik Schjesvold, Claudio Cerchione, Xavier P. Leleu et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France

Decaux Olivier, Ronan Garlantézec, Aurore PERROT, Margaret MACRO et autres

0 citationsClinical Hematology International

Accès ouvert 2026 articleOpenAlex

The Value of Progression-Free Survival in the Perspective of Patients with Multiple Myeloma and Treating Physicians: Research Findings from the US, EU4, UK, Brazil, and Japan

Aaron S. Rosenberg, Thomas Chalopin, Alison Bulkley, Kyla Finlayson et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Accès ouvert 2026 preprintOpenAlex

Subcutaneous Isatuximab by On-Body-Injector plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma: ISASOCUT study

Arthur Bobin, Cyrille Touzeau, Nicolas Branche, A. Perrot et autres

0 citationsResearch Square

2025 conference-abstractOpenAlex

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Aurore Perrot, Cyrille Hulin, Stéphanie Harel, Veronique Vitry et autres

0 citationsBlood

Accès ouvert 2025 conference-abstractOpenAlex

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Émilie Chalayer, Élisabeth Daguenet, Arthur Bobin, Thomas Fatrara et autres

1 citationBlood

Accès ouvert 2025 conference-abstractOpenAlex

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Bertrand Arnulf, Jérôme Lambert, Lionel Karlin, Cyrille Touzeau et autres

1 citationBlood

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.